 CONSHOHOCKEN, Pa., May 17, 2022 GLOBE NEWSWIRE -- Madrigal Pharmaceuticals, Inc. NASDAQ: MDGL, a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis NASH, announced today its management team will participate in two upcoming investor conferences: 